key: cord-0908741-aju0ogb6 authors: Avramovic, Gordana; McHugh, Tina; Connolly, Stephen P; Cullen, Walter; Lambert, John S title: Anticipate study protocol: Baseline profile and care outcomes of patients attending Mater Misericordiae University Hospital with COVID-19 infection date: 2021-01-18 journal: HRB Open Res DOI: 10.12688/hrbopenres.13091.2 sha: 760597d998b1a5f61036803bd1d15a4a0ecdd0bd doc_id: 908741 cord_uid: aju0ogb6 Background: While the COVID-19 pandemic is currently impacting on health and social care in Ireland, this impact is most marked in metropolitan Dublin. This is especially the case for the Mater Misericordiae University Hospital (MMUH) in Dublin’s North Inner, which is situated in an area where local socially deprived communities are at high risk of infection and of experiencing adverse outcomes. Aims: To determine baseline characteristics and longer-term care outcomes of COVID-19 patients presenting to / attending the Infectious Diseases Department at MMUH, including the virtual clinic. Methods: Retrospective study: we will retrospectively examine clinical records and extract anonymised data on patient demographics, baseline morbidity and outcomes. Prospective study: we will prospectively examine healthcare outcomes among patients who consent to follow up at two time points (three months, and six months to 12 months after discharge/onset of disease). Two patient groups will be assessed for morbid complications: those hospitalised with COVID infection and those followed-up remotely with confirmed COVID infection. Deliverables: The project will involve collaboration with Ireland’s Health Service Executive (HSE) Clinical Programmes and Ireland East Hospital Group to inform health service policies that will attenuate the adverse impacts of the COVID pandemic on population health. This research protocol will evaluate morbid complications of COVID depending on the severity of the disease. In response to reviewer 1, we have made the following changes: • Replaced 'severe COVID 19' with (as appropriate) the terms 'patients who required hospitalization' or 'patients requiring admission to intensive care' or 'patients requiring longer hospital stay' • Clinical and lab data to be collected is defined in the data collection instrument now included, and now summarized in the text of the paper. We are not collecting lab data outside of that defined in the paper. Data on medicines prescribed is being collected. In response to reviewer 2, we have made the following changes: • More detail has been added to the methodology. Data on deaths during hospital stay will be documented. For the retrospective study consent is not necessary as per current ethical approvals. Consent is necessary for the prospective study including study questionnaires. • Replaced 'severe COVID 19 with the terms 'patients who required hospitalization'. We will deal with the issue of patients who were attending the clinic for virtual monitoring who subsequently required hospital admission as follows: The cohort of all patients will be reported as a homogenous cohort. • We will examine the factors that are associated with adverse initial outcomes -deaths while an in-patient, treatment in intensive care, longer hospital stays. Logistic regression analysis of clinical and demographic variables will be conducted in this regard. • Pulmonary rehabilitation is being offered as part of the clinical care patients receive and thus, if clinically indicated as determined by the treating medical team. We will collect available data on Oxygen supplementation. There are no interventional arms in this study. The aim as I see it is to characterise the spectrum of disease. Neither the primary nor secondary end points are looking at the effects of rehabilitation. All of Ireland's population are susceptible to COVID-19 infection 5, 6 . Patients present with fever, cough, dyspnoea, fatigue, with some developing acute respiratory distress syndrome, multi-organ damage and secondary infection 7, 8 . Symptoms of COVID-19 infection vary between individuals, and according to disease severity 5, 7, 9 . Many are asymptomatic 10 , some show mild to moderate symptoms 5,7 although severe cases with acute respiratory distress syndrome, acute heart injury, and secondary bacterial infection have occurred 5, 9 . COVID-19 infection is linked to a range of blood, cellular, and genetic abnormalities 5, 7 . Those most at risk of severe illness as a result of infection include elderly males and/or people with underlying health conditions (e.g. diabetes, hypertension, heart disease, malnutrition) 5,10,11 . Older age and elevated D-dimer levels are associated with adverse outcomes 10 . Results of clinical trials will inform best treatment approaches but results of these are pending 5 . A systematic literature review from China assessed the prevalence and severity of COVID-19 12 . Healthcare outcomes after two months were assessed in another systematic review in the Middle East. However, longer-term outcomes were not assessed past two months, and there is a need to continue to study long term morbid complications 13 . In Ireland, we are only just beginning to understand the epidemiology of COVID-19 at a whole population level. The burden of COVID-19 disease in the North Dublin community and initial manifestations and longer-term complications of COVID-19 infection need to be further delineated. The Mater Misericordiae University Hospital (MMUH) in Dublin is located in an area with high levels of social deprivation and a high incidence of COVID-19 infection. While some patients assessed have required acute care hospitalisation, others, with milder disease, have been placed on a 'virtual COVID community monitoring programme' and managed in the outpatient setting. While COVID complications are likely to be more serious in those requiring hospitalisation, there is an evolving understanding that considerable morbidity can also occur in those with milder disease. We plan to establish and characterise the spectrum of disease and explore whether there are different clinical manifestations, and/or a greater risk of longer term complications in individuals who required hospitalization for COVID disease management; and individuals who tested positive and were supervised through the virtual COVID community monitoring programme. Results will be reported as a homogenous cohort. Since between six and 12 months, to evaluate them for long term complications. At each visit we will review their quality of life and wellbeing, both medically and psychologically. Subject enrolment and consenting process All patients who present or are referred during the COVID-19 outbreak will be eligible for the study. The requirement for consent was waived for the retrospective study by the ethics committee but is required for the prospective study. Data collection on patient deaths will be collected as part of the retrospective study. At the outset, anonymised data will be retrospectively collected on all patients who were admitted from 1 st March 2020. No consent will be requested for the retrospective review. The data will be fully anonymized. For the prospective study consent will be requested. When hospitalized patients are well enough and about to be discharged, they will be asked to participate in a prospective study including completing two interviewer-administered questionnaires and permit access to patient charts to review healthcare outcomes at three months and six to 12 months after discharge. For patients who have already been discharged, a member of the clinical COVID team will contact the patient by telephone to ask if they would be happy to be contacted to consider taking part in the follow-up study. If they accept, a consent form, patient information leaflet and a pre-stamped envelope for a return of correspondence will be sent out to them by post. Then a member of the research team will phone the patient to go through the consent form and information leaflet and answer any queries the patient may have regarding the study. If they decide to participate in the prospective study, participants will sign the consent form and it will be sent back to the study team via the pre-stamped envelope. A countersigned copy by authorised researchers will be posted back to them or given to them at their next attendance to the clinic. Virtual clinic patients are offered follow-up appointments after documentation of disease onset. When they present at the hospital for their follow-up appointment, a member of the research team will request their participation to the study. They will provide a patient information leaflet, give the patient time to read it and answer any questions. If the patient decides to participate to the study, they will sign an informed consent form 14 . Sample size and power calculations Based on current case reports from the Health Service Executive (HSE) Health Protection Surveillance Centre, we estimate that 500-1200 patients will present to the department during the study recruitment period. On 21 st June 2020, 798 patients had presented to the hospital (n=275) or virtual clinic (n=523) for COVID-19 assessment. Interventions to be measured -data collection and study instrument A study Gantt chart is available in Table 1 outlining the study timeframe and interventions. Anonymised aggregated data will be collected on baseline demographics / health outcomes measures from clinical records, to include age, gender, type of health insurance, date presented, date admitted, date discharged, COVID test result, other illnesses at admission and laboratory and test results. A data collection instrument is included for reference and provides the details of data collected for the study. We will examine the factors that are associated with adverse initial outcomes -deaths while an in-patient, treatment in intensive care, longer hospital stays. Logistic regression analysis of clinical and demographic variables will be conducted in this regard. 2. Prospective Study participants will be asked to complete two interviewer administered questionnaires (see Extended data) 14 at month three, and between month six and month 12 after discharge. The questionnaire will be administered in person or over the phone. They will report on their symptoms and quality of life through: a) Study specific questions examining process of care (specifically referral / admission for assessment / treatment of an acute medical or psychological problem). Did they experience any health-related problems and if so, what were they? b) General health status / quality of life will be assessed using the 12-Item Short Form Health Survey (SF-12), a multipurpose short-form generic measure of health status measuring eight domains: physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality (energy/ fatigue), social functioning, role limitations due to emotional problems and mental health (psychological distress and psychological well-being) 15 . c) Mental health symptoms, which are likely to be common at times of pandemic (especially depression / post-traumatic stress disorder) will be assessed using the Patient Health Questionnaire 2 (PHQ-2, a two-item screening questionnaire for depressive symptoms) 16 In addition consent will be requested to access medical records. Medical records will be analysed for morbid complications. Abnormal test results, as indicated by their COVID-19 care, will be recorded as relevant in the following categories: renal, respiratory, haematology, neurology and cardiology to provide a clinical picture of their health outcomes. To establish the likelihood for complications in each patient group and assess it by type. To assess impact on patients' overall quality of life and wellbeing, both medically and psychologically, at three and six to 12 months post infection by severity of disease. If clinically indicated we will review patients' cardiovascular, neurological, renal, pulmonary and haematological status. Plans to follow-up future patients will be better defined. Quality of follow-up of patients will be improved. Frequency counts will be presented in respect of categorical and ordinal data and mean/median/range will be presented in respect of numerical data. We will examine how variables (such as age, gender, pre-existing morbidity, type of healthcare insurance and living in a deprived local area) are associated with outcome measures (admitted, discharged, readmitted within seven or 30 days, physical/mental health outcomes including morbid complications) using a modified logistic regression analysis. Inferential statistics will be used to examine relationships between variables. With regards to data anonymisation, for the retrospective review of clinical records, all data will be anonymised at the time of data collection. Prospectively, all data will be coded and pseudonymised. Each participant will be given a numerical code, linked to their initials / date of birth and this will enable follow up. A list mapping these patient details (date of birth and initials) to numbers will be held by the research team. This list and all data will be stored as password protected files on a secure server at the UCD/MMUH Catherine McAuley Centre, 21 Nelson Street, Dublin 7. Study data will be retained for a period of five years after which it will be destroyed. Anonymised data will be made publicly available indefinitely. With regards to consent, a member of the clinical team will provide potential participants with written information regarding the study, including the reason for the study, the nature of the questions to be answered, the interview methods chosen and how the data will be analysed and used. Given the potentially sensitive nature of the study, the decision for the initial approach to come from the health or social care professional, while not obligatory, is in accordance with advice from the Data Protection Agency, which recommends that a third party should request people to participate in research and should not "surprise" people consulting with health or other agencies. Those who are interested in participating will be asked to meet with a member of the research team. Upon speaking with a member of the research team, potential participants will be encouraged to express any remaining concerns or issues requiring clarification, before signing a consent form. With regards to voluntary participation, it will be made explicit that non-participation in the study will not compromise the care they receive. No inducements to participate will be offered at recruitment. If an individual is unable to read, two impartial witnesses must be present during the entire informed consent discussion. The individual must give consent orally and, if capable of doing so, complete, sign and date the form together with the person responsible for collecting the informed consent. If the patient is unable to sign or to mark a document so as to indicate that his or her consent is given clearly to the investigator or another member of the investigating team, the consent process must be conducted in the presence of two impartial witnesses present at the same time and recorded in writing. The individual will be given one signed original informed consent form, the second original will be kept by the Principal Investigator. A copy will be placed in the patient's medical record. In designing this study, we have taken cognisance of best practice in conducting health research during times of major disasters 4 . The project will involve a collaboration with HSE Clinical Programmes to inform health service policies that will attenuate the adverse impacts of the COVID pandemic on population health. As such, outputs such as technical reports for stakeholders (at one, four, seven and 13 months) will be prioritised over the preparation of manuscripts for scientific journals, although such traditional outputs will also be disseminated. Within one month of award, the University College Dublin (UCD) Medicine website will host information on the project and provide regular updates to the general public. A weekly email bulletin will be sent to stakeholder agencies to contain updated information on weekly/cumulative total number of cases, hospital admissions, discharges and re-admissions. Five publications are expected from this work: general symptoms, pulmonary complications, cardiac complications, neurological complications and general quality of life. The anonymized, FAIRified study data will be made available upon publication of research articles. Data will be made available via the Zenodo repository or a suitable repository will be chosen as advised by publishing journals. Study data for article published to date is available as a pre-print at: http://doi.org/10.5281/zenodo.4327641 19 . On the 29 th June 2020 the retrospective study had been completed for the first 100 patients and published 19 . Amalgamation of retrospective results for a larger number of patients is in progress. The prospective study is recruiting patients and questionnaires are in progress. My main concern is that the proposed methodology is vague and this aspect of the study would benefit from more detail. What about patient deaths -are these to be excluded and only survivors included? As written patients who die will not be captured as consent is essentially at discharge. This should be discussed. What severity scale of disease will be utilised to stratify patients and decide on admission or outpatient management? In response to reviewer 2, we have made the following changes: More detail has been added to the methodology. Data on deaths during hospital will be documented. For the retrospective study consent is not necessary as per current ethical approvals. Consent is necessary for the prospective study including study questionnaires. What scale will be utilised to dictate on-going patient management and categorise patients for data analysis? Replaced 'severe COVID 19 with the terms 'patients who required hospitalization'. We will deal with the issue of patients who were attending the clinic for virtual monitoring who subsequently required hospital admission as follows: The cohort of all patients will be reported as a homogenous cohort. We will examine the factors that are associated with adverse initial outcomes -deaths while an in-patient, treatment in intensive care, longer hospital stays. Logistic regression analysis of clinical and demographic variables will be conducted in this regard. Pulmonary rehabilitation is being offered as part of the clinical care patients receive and thus, if clinically indicated as determined by the treating medical team. We will collect available data on Oxygen supplementation. There are no interventional arms in this study. The aim as I see it is to characterise the spectrum of disease. Neither the primary nor secondary end points are looking at the effects of rehabilitation. Patients with no oxygen requirements were managed from home. Assessed as stable in the Emergency Room. The patient cohort is dealt with as a homogenous cohort. Why the Borg scale for breathlessness? Will mMRC be measured? Both are validated and acceptable for a study such as this. We have opted for the Borg scale. with COVID-19 in Wuhan, China: a retrospective cohort study PubMed Abstract |� Publisher Full Text |� Free Full Text Prevalence and Severity of Corona Virus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis Long-term Clinical Outcomes in Survivors of Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome Coronavirus Outbreaks After Hospitalisation or ICU Admission: A Systematic Review and Meta-Analysis Anticipate Study Baseline Profile and Care Outcomes of Patients attending Mater Misericordiae University Hospital with Covid-19 Infection A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity The Patient Health Questionnaire-2: validity of a two-item depression screener The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5). 2015. Reference Source The Borg dyspnoea score: a relevant clinical marker of inspiratory muscle weakness in amyotrophic lateral sclerosis What is the clinical course of patients hospitalised for COVID-19 treatment Ireland: a retrospective cohort study in Dublin's North Inner City (the 'Mater 100'). PREPRINT (Version 1) available at Research Square. 2020. Publisher Full Text 1. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 Reference Source 2. World Health Organisation: Coronavirus disease (COVID-19) Situation Report- 128 27 Reference Source Latest Statistics and Updates - COVID-19 Institute of Medicine: Enabling Rapid and Sustainable Public Health Research During Disasters: Summary of a Joint Workshop by the Institute of Medicine and the U.S. Department of Health and Human Services Review of the 2019 Novel Coronavirus (SARS-CoV-2) Based on Current Evidence Clinical Characteristics of 140 Patients Infected With SARS-CoV-2 in Wuhan, China. Allergy. 2020. PubMed Abstract |� Publisher Full Text Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study MedRXiv Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study PubMed Abstract |� Publisher Full Text |� Free Full Text Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center PubMed Abstract |� Publisher Full Text |� Free Full Text Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital Clinical course and risk factors for mortality of Reviewer Expertise: My research has examined airway remodelling in airways diseases including asthma and post-transplant obliterative bronchiolitis. My current research is mainly focused on asthma, in particular on how aspiration and differences in the microbiome influence airway inflammation and remodelling in severe asthma. I am a co-investigator on HRB-funded research examining the role of compliance and inhaler technique in asthma management. surrounding areas although with clusters in other counties. However, more recently there appears to be increasing numbers nationally. Many Irish hospitals including The Mater have been affected. The data generated by this study will provide useful insight of both National and International relevance.My main concern is that the proposed methodology is vague and this aspect of the study would benefit from more detail.What about patient deaths -are these to be excluded and only survivors included? As written patients who die will not be captured as consent is essentially at discharge. This should be discussed.What severity scale of disease will be utilised to stratify patients and decide on admission or outpatient management? What scale will be utilised to dictate on-going patient management and categorise patients for data analysis? INEWS vs NCP/ITS Respiratory Scale or both (or other)? Are the datasets clearly presented in a useable and accessible format? Not applicable Competing Interests: No competing interests were disclosed.Reviewer Expertise: My research has examined airway remodelling in airways diseases including asthma and post-transplant obliterative bronchiolitis. My current research is mainly focused on asthma, in particular on how aspiration and differences in the microbiome influence airway inflammation and remodelling in severe asthma. I am a co-investigator on HRB-funded research examining the role of compliance and inhaler technique in asthma management. The researchers plan to establish and characterize the spectrum of COVID-19 disease and explore whether there are different clinical manifestations, and/or a greater risk of longer term complications between two groups: 1) individuals admitted to hospital for more severe COVID disease management; and 2) individuals who tested positive and were supervised through the virtual COVID community monitoring program.It may be more pragmatic to simply study all hospitalized patients (regardless whether defined as more severe or not) versus all individuals who were monitored through the community program. However, if the definition "severe COVID-19" is used it should be defined more clearly. Also there is a need to explain how the researchers will deal with patients who started off with a virtual community monitoring but with more progressive disease were then hospitalized. Obviously they still should stay in the monitoring group rather than then adding them to the hospitalized group.Clearly this study is very timely as the COVID-19 pandemic is unfolding and many clinical and epidemiological questions are still unanswered.Nevertheless, the overall proposal is very general and would really need some more detailed description of what kind of clinical and lab data will be collected or is available. It is stated that "….other illnesses at admission and laboratory and test results…." will be captured but what diseases and what lab values are they talking about? This really would need to be defined upfront. How will the researchers deal with certain diseases or co-infections which may warrant additional data. For example in case of HIV co-infection will there be an attempt to gather additional data on CD4 count or viral load? What about co-medications which are supposingly affecting risk or outcome of COVID-19 disease; will they be captured as well?A strength of the proposal is the use of standardized questionnaires to capture the impact of a COVID-19 infection on general health and mental well-being.Is the rationale for, and objectives of, the study clearly described? Yes Are the datasets clearly presented in a useable and accessible format? Not applicable We will deal with the issue of patients who were attending the clinic for virtual monitoring who subsequently required hospital admission as follows: The cohort of all patients will be reported as a homogenous cohort.• Clinical and lab data to be collected is defined in the data collection instrument now included, and now summarized in the text of the paper. We are not collecting lab data outside of that defined in the paper. Data on medicines prescribed is being collected. No competing interests were disclosed.